<DOC>
	<DOCNO>NCT02215369</DOCNO>
	<brief_summary>The VenaCure EVLT 400 µm Fiber Kit currently market treatment varicose vein . AngioDynamics , Inc. , company manufacturer VenaCure device , sponsor study assess safety effectiveness VenaCure EndoVenous Laser Treatment ( EVLT ) 400 µm Fiber Kit treatment incompetent perforator vein ( IPVs ) . The VenaCure EVLT 400 µm Fiber Kit previously study AngioDynamics ablation IPVs .</brief_summary>
	<brief_title>Prospective Safety Effectiveness Study : VenaCure Endovenous Laser Treatment ( EVLT ) 400 µm Fiber Procedure Kit Treatment Incompetent Perforator Veins</brief_title>
	<detailed_description>This single-arm , prospective , multicenter , non-blinded clinical trial . Study data summarize submitted FDA premarket notification treat subject complete 3 month visit . Longer term followup perform publication purpose . Patients diagnose incompetent Perforator Veins ( IPV 's ) meet inclusion none exclusion criterion eligible study .</detailed_description>
	<mesh_term>Venous Insufficiency</mesh_term>
	<criteria>INCLUSION CRITERIA Patients require fulfill follow criterion include study : 1 . Is ≥ 18 year age 2 . IPV ( ) treat outward flow duration ≥ 0.5 sec immediately manual release manual compression 3 . IPV ( ) treat diameter ≥ 3.5 mm ( measure level fascia ) locate superior foot distal ankle 4 . Has diagnose refractory symptomatic disease ( CEAP Class 4b Class 6 ) attributable IPV treat 5 . Has palpable pedal pulse study limb 6 . Any pathologic superficial saphenous vein previously eliminate do least 30 day prior study procedure 7 . Is able ambulate 8 . Is able comprehend sign Informed Consent Form ( ICF ) participate study 9 . Is willing able comply Clinical Investigation Plan followup schedule EXCLUSION CRITERIA Patients exclude participation study meet follow : 1 . Has venous insufficiency secondary venous obstruction proximal intend treatment site 2 . Has thrombus vein segment treat 3 . Has know peripheral arterial disease 4 . Has BMI calculation ( BMI = W / H2 ) ≥40kg/m2 5 . Is undergo active anticoagulant therapy Deep VeinThrombosis condition ( e.g. , warfarin , Q10 inhibitor low molecular weight heparin ) history Deep Vein Thrombosis within last 6 month hypercoagulable state . 6 . Has prior venous procedure study limb within last 30 day ( include limit , thrombolysis / thrombectomy / stenting / ablation / phlebectomy / sclerotherapy ) 7 . Has undergone expect undergo major surgery within 30 day prior within 90 day follow study procedure 8 . Has condition , judge treat physician , may jeopardize patient 's wellbeing and/or confound result soundness study 9 . Is pregnant lactate time study procedure intend become pregnant within 90 day follow study procedure 10 . Is participate another clinical study contraindicative treatment outcome investigation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>